Paying users zone. Data is covered by 
.
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Analysis of Solvency Ratios
Difficulty: Beginner
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Bristol-Myers Squibb Co., solvency ratios
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Debt Ratios | ||||||
| Debt to equity | |
|
|
|
|
|
| Debt to capital | |
|
|
|
|
|
| Debt to assets | |
|
|
|
|
|
| Financial leverage | |
|
|
|
|
|
| Coverage Ratios | ||||||
| Interest coverage | |
|
|
|
|
|
| Fixed charge coverage | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s financial leverage ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.’s interest coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co.’s fixed charge coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Debt to Equity
Bristol-Myers Squibb Co., debt to equity calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term debt obligations | |
|
|
|
|
|
| Long-term debt, excluding current portion | |
|
|
|
|
|
| Total debt | |
|
|
|
|
|
| Total Bristol-Myers Squibb Company shareholders’ equity | |
|
|
|
|
|
| Solvency Ratio | ||||||
| Debt to equity1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Debt to Equity, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Debt to Equity, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Debt to equity = Total debt ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. |
Debt to Capital
Bristol-Myers Squibb Co., debt to capital calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term debt obligations | |
|
|
|
|
|
| Long-term debt, excluding current portion | |
|
|
|
|
|
| Total debt | |
|
|
|
|
|
| Total Bristol-Myers Squibb Company shareholders’ equity | |
|
|
|
|
|
| Total capital | |
|
|
|
|
|
| Solvency Ratio | ||||||
| Debt to capital1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Debt to Capital, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Debt to Capital, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. |
Debt to Assets
Bristol-Myers Squibb Co., debt to assets calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Short-term debt obligations | |
|
|
|
|
|
| Long-term debt, excluding current portion | |
|
|
|
|
|
| Total debt | |
|
|
|
|
|
| Total assets | |
|
|
|
|
|
| Solvency Ratio | ||||||
| Debt to assets1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Debt to Assets, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Debt to Assets, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. |
Financial Leverage
Bristol-Myers Squibb Co., financial leverage calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | |
|
|
|
|
|
| Total Bristol-Myers Squibb Company shareholders’ equity | |
|
|
|
|
|
| Solvency Ratio | ||||||
| Financial leverage1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Financial Leverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Financial Leverage, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Financial leverage = Total assets ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s financial leverage ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018. |
Interest Coverage
Bristol-Myers Squibb Co., interest coverage calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings attributable to BMS | |
|
|
|
|
|
| Add: Net income attributable to noncontrolling interest | |
|
|
|
|
|
| Add: Income tax expense | |
|
|
|
|
|
| Add: Interest expense | |
|
|
|
|
|
| Earnings before interest and tax (EBIT) | |
|
|
|
|
|
| Solvency Ratio | ||||||
| Interest coverage1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Interest Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Interest Coverage, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.’s interest coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Fixed Charge Coverage
Bristol-Myers Squibb Co., fixed charge coverage calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings attributable to BMS | |
|
|
|
|
|
| Add: Net income attributable to noncontrolling interest | |
|
|
|
|
|
| Add: Income tax expense | |
|
|
|
|
|
| Add: Interest expense | |
|
|
|
|
|
| Earnings before interest and tax (EBIT) | |
|
|
|
|
|
| Add: Operating lease expense | |
|
|
|
|
|
| Earnings before fixed charges and tax | |
|
|
|
|
|
| Interest expense | |
|
|
|
|
|
| Operating lease expense | |
|
|
|
|
|
| Fixed charges | |
|
|
|
|
|
| Solvency Ratio | ||||||
| Fixed charge coverage1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Fixed Charge Coverage, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co.’s fixed charge coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |